In Safety first: Assessing drugs early can preclude regulatory and health issues, a new ebook developed by a collaboration with some of our top scientists, we discuss how to create a thorough and well-executed drug development plan with proper risk assessment so you can be confident about the safety of your drug.
Every drug begins its journey to the clinic with preclinical testing to help predict whether the compound will work and if there is any risk to the patient. One required aspect of this risk assessment is to look for potential drug-drug interactions (DDI). This ebook will explore the regulatory expectations of drug developers to research DDI potential, the relationship between a drug’s characteristics and DDI risk, the methods available to test those characteristics, and considerations for drug developers to plan and successfully navigate DDI risk assessment.
- Understand the regulatory expectations for drug developers with respect to drug-drug interaction studies, particularly in the investigational new drug application process.
- Understand the relationship between a drug’s absorption, distribution, metabolism, and excretion (ADME) characteristics and the risk for drug-drug interactions.
- Learn about the methods available for testing drug characteristics that could impact the risk for drug-drug interactions.
About the Authors
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback